The journal
Open the journal →The conversation starts in the journal — be the first to post.
About Eleusis
Eleusis is a pharmaceutical company that is developing serotonin 5-HT2A receptor agonists related to serotonergic psychedelics as novel anti-inflammatory drugs to treat inflammatory diseases. It is interested in developing the drugs for treatment of conditions like asthma, cardiovascular disease, and Crohn's disease, but is initially focusing on ophthalmology.
Everything about Eleusis →